Associated Papers
Discovery of a MET -driven monogenic cause of steatotic liver disease.
Pinto E Vairo F et al.
Hepatology (baltimore, Md.), 2025
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).
Ugolini A et al.
Journal of Medicinal Chemistry, 2016
27355974 (PubMed )
Supplement: jm6b00280_si_001.pdf
Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C et al.
Biochemistry, 2005
Select a paper to view details